help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Armanini, D.
Right arrow Articles by Adam, W. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Armanini, D.
Right arrow Articles by Adam, W. R.

Endocrinology, Vol 111, 1683-1686, Copyright © 1982 by Endocrine Society

ARTICLES

The mechanism of mineralocorticoid action of carbenoxolone

D Armanini, I Karbowiak, Z Krozowski, JW Funder and WR Adam

The principal side effects of the drug carbenoxolone (Biogastrone; 18 beta-glycyrrhetinic acid sodium hemisuccinate) are sodium retention, hypokalemic alkalosis, suppressed plasma renin, and hypertension. In previous animal studies, carbenoxolone appeared not to have intrinsic mineralocorticoid activity but, rather, to enhance aldosterone action by displacing it from nonspecific binding sites. We here report studies showing that carbenoxolone has demonstrable affinity for rat kidney mineralocorticoid receptors, intrinsic mineralocorticoid activity in the adrenalectomized rat at doses consistent with its receptor affinity, and, in addition, a powerful action of amplifying the electrolyte effects of near-maximal doses of aldosterone.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
K. J. Biller, R. J. Unwin, and D. G. Shirley
Distal tubular electrolyte transport during inhibition of renal 11{beta}-hydroxysteroid dehydrogenase
Am J Physiol Renal Physiol, January 1, 2001; 280(1): F172 - F179.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. Kato, H. Sasano, S. Ohara, H. Sekine, S. Mochizuki, T. Mune, K. Yasuda, H. Nagura, T. Shimosegawa, T. Toyota, et al.
Coexpression of Mineralocorticoid Receptors and 11{beta}-Hydroxysteroid Dehydrogenase 2 in Human Gastric Mucosa
J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2568 - 2573.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Cell Physiol.Home page
D. J. Morris, S. A. Latif, M. D. Rokaw, C. O. Watlington, and J. P. Johnson
A second enzyme protecting mineralocorticoid receptors from glucocorticoid occupancy
Am J Physiol Cell Physiol, May 1, 1998; 274(5): C1245 - C1252.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
J. Funder, P. Pearce, R Smith, and A. Smith
Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated
Science, October 28, 1988; 242(4878): 583 - 585.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1982 by The Endocrine Society